In This Article:
Looking at Vivoryon Therapeutics N.V.'s (AMS:VVY ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold.
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we would consider it foolish to ignore insider transactions altogether.
Check out our latest analysis for Vivoryon Therapeutics
The Last 12 Months Of Insider Transactions At Vivoryon Therapeutics
In the last twelve months, the biggest single purchase by an insider was when Chairman of the Management Board Frank Weber bought €158k worth of shares at a price of €7.90 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price (being €2.29). It's very possible they regret the purchase, but it's more likely they are bullish about the company. In our view, the price an insider pays for shares is very important. As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. The only individual insider to buy over the last year was Frank Weber.
Frank Weber bought 33.95k shares over the last 12 months at an average price of €7.93. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.
Insider Ownership Of Vivoryon Therapeutics
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 12% of Vivoryon Therapeutics shares, worth about €6.9m, according to our data. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. Whilst better than nothing, we're not overly impressed by these holdings.
So What Do The Vivoryon Therapeutics Insider Transactions Indicate?
The fact that there have been no Vivoryon Therapeutics insider transactions recently certainly doesn't bother us. But insiders have shown more of an appetite for the stock, over the last year. We'd like to see bigger individual holdings. However, we don't see anything to make us think Vivoryon Therapeutics insiders are doubting the company. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Vivoryon Therapeutics. To that end, you should learn about the 5 warning signs we've spotted with Vivoryon Therapeutics (including 3 which are significant).